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Lack of an Effect of Oral Iron Administration on
Mycophenolic Acid Pharmacokinetics in 
Stable Renal Transplant Recipients
Daniele K. Gelone, Pharm.D., Jeong M. Park, M.S., Pharm.D., and Kathleen D. Lake, Pharm.D.
Study Objectives. To determine if coadministration of polysaccharide iron complex
and slow-release ferrous sulfate alter the absorption of mycophenolic acid (MPA),
and to examine the potential influence of dosing relative to mycophenolate
mofetil (MMF) administration and the effect of immediate- versus sustained-
release iron products on the steady-state pharmacokinetics of MPA.
Design. Prospective, open-label, three-phase, crossover, steady-state
pharmacokinetic study.
Setting. National Institutes of Health–sponsored General Clinical Research
Center at a university medical center.
Patients. Twelve adult (mean age 50 yrs) renal transplant recipients who were
receiving concomitant iron and MMF maintenance therapy.
Intervention. Oral iron therapy was coadministered with MMF on days -6–0,
MMF was administered alone on days 1–8 (control phase), then oral iron
therapy was administered 2 hours after MMF administration on days 9–16.
Measurements and Main Results. Baseline demographics, concurrent drug
regimens, and clinical laboratory values were assessed.  Blood samples were
obtained at baseline and at 1, 2, 3, 4, 6, 8, and 12 hours after MMF
administration on days 0, 8, and 16.  The MPA levels were measured by
high-performance liquid chromatography. We found no significant
differences in the dose-standardized area under the concentration-time
curve from 0–12 hours (AUC0–12) for MPA between the control phase
(39.66 ± 8.70 mg•hr/L) and the concomitant ferrous sulfate or dose-
separated ferrous sulfate (37.56 ± 9.95 or 32.84 ± 8.43 mg•hr/L,
respectively, p>0.05) phases.  Dose-standardized AUC0–12 values for MPA
did not significantly differ after the concomitant administration of
polysaccharide iron complex from that of the control phase (48.46 ± 9.68
and 43.80 ± 9.46 mg•hr/L, respectively, p=0.065).  However, the AUC0–12
for MPA significantly increased when polysaccharide iron complex was
administered 2 hours after MMF (53.41 ± 11.75 mg•hr/L, p=0.012).
Maximum concentrations and times to reach maximum concentrations
remained consistent across all study phases in each arm of the trial
(p>0.05).
Conclusion. Multiple doses of iron therapy—slow-release ferrous sulfate, or
polysaccharide iron complex—did not significantly reduce systemic
exposure to MMF, as measured by using AUC0–12 values.
Key Words: mycophenolate mofetil, pharmacokinetics, renal transplantation,
drug interactions, ferrous sulfate, polysaccharide iron complex.
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Mycophenolate mofetil (MMF) is a key
component of modern immunosuppression and
is routinely used to prevent rejection in transplant
recipients.  Several pivotal multicenter clinical
trials involving kidney transplant recipients
demonstrated a 50% reduction in acute rejection
with MMF-based regimens compared with
azathioprine-based regimens.1–5 Evidence further
demonstrated a significant correlation between
the probability of rejection and the concentration-
time curve for mycophenolic acid (MPA).6–10
Investigators evaluating the relationship between
rejection and systemic exposure to MPA reported
thresholds that minimize the risk of rejection; the
area under the concentration-time curve from
0–12 hours (AUC0–12) for MPA was greater than
30 mg•hour/L, and the predose plasma concen-
tration for MPA was greater than 1.0 mg/L.7, 11
However, abbreviated MPA-sampling strategies
have proven preferable over the use of predose
concentrations, particularly in the early period
after transplantation, owing to a strengthened
correlation with the area under the concentration-
time curve and with rejection in the case of
AUC0–12.12, 13
After oral administration, MMF is rapidly
absorbed and presystemically hydrolyzed to its
active form, MPA, in the liver.14 Glucuronyl
transferase then metabolizes MPA to MPA
glucuronide, an inactive metabolite.15 This
metabolite also undergoes considerable
enterohepatic recirculation, which possibly
contributes to the biphasic pharmacokinetic
profile of MPA.16–18 Although MMF alone offers
excellent bioavailability, it remains potentially
susceptible to chelation interactions when it is
coadministered with other drugs, including
aluminum- and/or magnesium-containing
antacids or cholestyramine.15, 16, 19–21 In addition,
data from a crossover, single-dose study of
healthy volunteers suggested that the systemic
exposure to MPA decreased by 89% after iron was
concomitantly administered with a single dose of
MMF.20 This effect was attributed to the theoretical
development of an insoluble iron-MMF complex.
Given the concentration-efficacy relationship
reported in the literature, transplant recipients
receiving an MMF-based regimen who require
iron supplementation may incur an increased
risk for acute rejection secondary to reduced
overall systemic exposure to MPA from such an
interaction.
This study was designed to determine if
coadministration of two commonly prescribed
iron formulations—polysaccharide iron complex
and sustained release ferrous sulfate—alter the
absorption of MPA in stable renal transplant
recipients.  In addition, we examined the poten-
tial influence of timing of the dosing relative to
MMF administration and the effect of immediate-
versus sustained-release iron products on the
steady-state pharmacokinetics of MPA.
Methods
The institutional review board of the University
of Michigan approved the study protocol.  All
patients gave written informed consent before any
study procedures were started.
Study Subjects
Patients were eligible for enrollment if they
were at least 18 years old, if they received renal
allografts from a living or deceased donor, if they
were in stable condition, if at least 6 months had
passed since transplantation, and if they were
concomitantly receiving slow-release ferrous
sulfate or polysaccharide iron complex with
MMF maintenance therapy. Eligibility criteria
also included no acute rejection in the 3 months
before study entry, achievement of therapeutic
trough levels of cyclosporine (usually 100–150
ng/ml) or tacrolimus (usually 5–10 ng/ml) as
defined in the protocol of the transplant center,
and no recent dosage adjustments to cyclosporine
(United States Pharmacopeia, modified) or
tacrolimus within 2 weeks before study entry.
Patients were excluded if they received other
organ transplants in addition to kidney transplants
or if they were pregnant or breastfeeding.
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Immunosuppression consisted of a standard
protocol:  a calcineurin inhibitor, cyclosporine
(Neoral, Novartis Pharmaceuticals Corp., East
Hanover, NJ; or Gengraf, Abbott Laboratories,
Abbott Park, IL), or tacrolimus (Prograf, Astellas
Pharma US, Inc., Deerfield, IL) in combination
with twice-daily MMF and daily prednisone.
Previously prescribed formulations of slow-
release ferrous sulfate (Slow-Fe; Novartis
Consumer Health, Inc., Parsippany, NJ) or
polysaccharide iron complex (Niferex-150; Ther-
Rx, Bridgeton, MO) were maintained.
Study Design
This study was a prospective, open-label, three-
phase, crossover, steady-state pharmacokinetic
study.  Patients were instructed to avoid drinking
alcohol or taking any new drugs for 1 week
before the study and throughout the trial.
Patients were assigned to study arms according
to their previously prescribed iron formulation of
slow-release ferrous sulfate or polysaccharide
iron complex.  In each arm, slow-release ferrous
sulfate or polysaccharide iron complex was
coadministered with the oral morning dose of
MMF on days -6–0.  On days 1–8, MMF was
taken alone (washout period).  On days 9–16,
iron products were taken 2 hours after the dose
of MMF.
The AUCs for MPA were measured on days 0,
8, and 16.  Before each blood sampling day,
patients fasted overnight for at least 10 hours,
but water was allowed ad libitum.
After completion of the study, patients were
eligible to cross over to the opposite study arm
with the approval of their physician.  Patients
continued to fast 4 hours after the morning dose
of MMF but were allowed to drink water ad
libitum.  All patients received standardized meals
5 and 10 hours after the administration of MMF.
Each patient received the same oral MMF dose
(500–1000 mg) twice/day throughout the trial.
Venous blood samples were drawn at baseline
before the morning dose of MMF and at 1, 2, 3,
4, 6, 8, and 12 hours after the ingestion of MMF.
Samples were immediately centrifuged, and
plasma was frozen at -80°C until analysis.
Renal function was evaluated by measuring
serum creatinine concentrations.
End Points
The primary end point was the AUC0–12 for
MPA. Concentrations of MPA and MPA
glucuronide were measured by using validated
high-performance liquid chromatography.  The
assay for MPA–MPA glucuronide in biologic
specimens was developed in the Drug Laboratory
at the Mayo Clinic, Rochester, Minnesota.
For each sample, two tubes were required.  The
test involved direct measurement of serum MPA
levels and replicated analyses of serum treated
with glucuronidase to measure total hydrolyzable
MPA levels.  The difference between unconjugated
and total MPA results allowed us to calculate the
concentration of MPA glucuronide.  One tube
labeled A was for MPA, and one tube labeled B
was for MPA glucuronide. To tube A, 200 µl of
the standards, controls, and samples were added,
and to tube B, 50 µl and 150 µl of blank serum
were added.  To only tube B, 100 µl of 1:10
glusulase in sodium acetate buffer at pH 6.0 were
added and incubated for 10 minutes at 37°C; 100
µl were pipetted into tube B.  To both tubes, 100
µl of the internal standard (5 µg/ml zomepirac in
acetonitrile) were added.  Excess sodium sulfate
was added and centrifuged, and the supernatant
was removed.  The extract was dried under
nitrogen at 30°C and reconstituted in 200 µl of
the mobile phase.
Using a chromatography system (Class-VP LC;
Shimadzu Scientific Instruments, Columbia,
MD), 30 µl of the reconstituted sample were
placed onto an high-performance liquid
chromatography guard column (2 cm x 4.6 mm,
5 µm) and an analytical column (5 cm x 4.6 mm,
5 µm) (both Discovery C18; Supelco, Sigma-
Aldrich, Bellefonte, PA) at ambient temperature.
Chromatographic separation was achieved by
delivering isocratic solvent with a mobile phase
of 20% acetonitrile and 80% triethylamine-
phosphate buffer at pH 7.0 (final concentration
25% triethylamine and 1.875 mmol/L potassium
phosphate buffer) with a flow rate of 2.0
ml/minute.  Detection was achieved by monitoring
the absorbance at 213 nm.  We eluted MPA at 2.8
minutes and the internal standard at 6.75
minutes.
Concentrations were calculated by comparing
peak-height ratios of the drug with those of the
internal standard.  The lower limit of quantifi-
cation was defined as 0.5 µg/ml.  Intraday
variability was defined as less than 10%, and
interday variability was not applicable.  Secondary
end points were the maximum concentration
(Cmax) and the time to reach Cmax (Tmax).  Both
Cmax and Tmax were determined directly from
measured values.
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Statistical Analysis
The patients’ characteristics were summarized
by using descriptive statistics.  Individual
AUC0–12 values were calculated by using the
linear trapezoidal and logarithmic trapezoidal
approximation for increasing and decreasing
plasma concentrations, respectively.  Values were
dose normalized to MMF 1 g.  A paired t test was
used to compare experimental-phase AUCs for
MMF plus iron products taken concomitantly or
2 hours apart were compared with those from the
control phase of MMF alone.  Prospective power
calculations indicated that a minimum of eight
patients in each arm were required to detect a
30% difference in AUC0–12 values for MPA with
80% likelihood if we assumed a two-sided α of
0.05.  Statistical analyses were performed by
using software (Statistical Package for the Social
Sciences for Windows, version 11.0; SPSS Inc.,
Chicago, IL).
Results
Twelve patients were screened and enrolled in
the study. One subject was prematurely
withdrawn from the study because of a marked
change in renal function after day 8 of the
pharmacokinetic study.  After the sequence for
slow-release ferrous sulfate was completed, one
patient consented to switch iron formulations
and completed the sequence for polysaccharide
iron complex.  Data from seven patients in the
arm for polysaccharide iron complex and five in
the arm for slow-release ferrous sulfate were
analyzed.
Effect of Polysaccharide Iron Complex on the
Pharmacokinetics of MPA
Table 1 summarizes the patients’ baseline
demographics.  Immunosuppressive therapy
consisted of primarily cyclosporine (Neoral in
five patients and Gengraf in one), MMF, and
prednisone.  One patient received tacrolimus,
MMF, and prednisone.  Each patient received 150
mg of elemental iron.  The patient population
was primarily Caucasian and first-time transplant
recipients.  Serum creatinine concentration
measurements remained constant between each
study phase (p=0.407), with a maximum
difference of 0.2 mg/dl between study phases.
Table 2 shows the calculated pharmacokinetic
parameters reflecting coadministration of MMF
and polysaccharide iron complex.  During the
control phase, calculated AUC0–12 values for MPA
were greater than 30 mg•hour/L for all subjects
(range 35.4–56.4 mg•hr/L) but one, whose value
was 27.8 mg•hour/L. The value of 30 mg•hour/L
is an established threshold for a diminished risk
of acute rejection.7, 11 The mean estimated
AUC0–12 value for MPA when MMF was coad-
ministered with polysaccharide iron complex
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Table 1.  Baseline Demographic Characteristics
Polysaccharide Slow-Release
Iron Complex Ferrous Sulfate
Group Group
Characteristic (n=7) (n=5)
Mean ± SD
Age (yrs) 50.28 ± 8.71 51.00 ± 14.45
Time after transplantation (mo) 47.00 ± 45.22 51.00 ± 29.29
Weight (kg) 87.11 ± 18.57 108.54 ± 29.29
No. (%) of Patients
Sex
Male 3 (43) 4 (80)
Female 4 (57) 1 (20)
Caucasian 6 (86) 5 (100)
Deceased donor transplant 3 (43) 3 (60)
First transplant 6 (86) 5 (100)
Diabetes mellitus 1 (14) 3 (60)
Cause of end-stage renal disease
Diabetes mellitus 1 (14) 2 (40)
Polycystic kidney disease 2 (29) 0 (0)
Glomerulonephritis 4 (57) 2 (40)
Other 0 (0) 1 (20)
Cyclosporine-based regimena 6 (86) 5 (100)
aCyclosporine U.S. Pharmacopeia, modified.
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(48.46 ± 9.68 mg•hr/L) was similar to the control
value for MMF alone (43.80 ± 9.46 mg•hr/L).
Although the difference was not significantly
different (p=0.065), we observed an 11.8% mean
increase in the AUC0–12 for MPA during the
concomitant-dosing phase versus the MMF-alone
phase.  In addition, mean AUC0–12 values were
significantly greater when polysaccharide iron
complex was administered 2 hours after MMF
than in the control phase (p=0.012).  This
difference resulted in an observed mean increase
of 22.7% for MPA exposure.  Observed Cmax and
Tmax were similar between the control arm and
the concomitant or dose-separation arm; mean
Cmax values were slightly increased in both the
concomitant and dose-separation phases.
Effect of Slow-Release Ferrous Sulfate on the
Pharmacokinetics of MPA
Tables 1 and 3 summarize the patients’
characteristics and calculated pharmacokinetic
parameters, respectively, in the slow-release
ferrous sulfate study.  The mean ± SD dose of
elemental iron was 83.0 ± 42.7 mg.  Renal
function, as evaluated by using serum creatinine
concentrations, remained stable throughout all
study phases (p=0.47), with no change exceeding
0.6 mg/dl.  All subjects received immunosuppres-
sion based on cyclosporine (Neoral in three and
Gengraf in two) with MMF and prednisone.
All calculated AUC0–12 values for MPA in the
control phase were therapeutic and ranged from
30.4–54.0 mg•hour/L.  No difference was observed
in mean AUC0–12 values between the control
phase and the concomitant phase (p=0.716).
The mean AUC0–12 value for the dose-separation
phase was similar to the control value (p=0.236).
Results for Cmax and Tmax remained consistent
between study phases (control vs concomitant or
separation arm); Cmax values were slightly
reduced in both the concomitant and dose-
separation phases (p=0.32 and p=0.241,
respectively).
Discussion
The impetus for this trial came from a previous
report that demonstrated an 89% reduction in the
AUC0–12 for MPA after MMF 1000 mg was
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Table 2.  Pharmacokinetic Parameters from the Polysaccharide Iron Complex Study
MMF + Polysaccharide Iron Complex
Parameter MMF Alone Coadministered 2 Hours Apart
Median (Range)
MPA AUC0–12 (mg•hr/L) 45.26 (27.84–56.73) 51.91 (36.33–57.75) 57.59 (33.24–69.21)
Mean ± SD
MPA AUC0–12 (mg•hr/L) 43.80 ± 9.46 48.46 ± 9.68 53.41± 11.75a
MPA C0 (mg/L) 2.51 ± 1.05 2.84 ± 1.83 2.39 ± 2.00
Cmax (mg/L) 9.53 ± 5.12 12.46 ± 5.90 12.6 ± 3.77
Tmax (hrs) 1.70 ± 1.24 1.57 ± 1.13 1.57± 0.98
MMF = mycophenolate mofetil; AUC0–12 = area under the concentration-time curve from 0–12 hours; MPA=
mycophenolic acid; C0 = predose plasma concentration; Cmax = maximum concentration; Tmax = time to reach Cmax.
ap=0.012 versus MMF alone.
Table 3.  Pharmacokinetic Parameters from the Slow-Release Ferrous Sulfate Study
MMF + Slow-Release Ferrous Sulfate
Parameter MMF Alone Coadministered 2 Hours Apart
Median (Range)
MPA AUC0–12 (mg•hr/L) 38.30 (30.44–54.04) 36.37 (27.14–53.22) 37.77 (23.53–41.21)
Mean ± SD
MPA AUC0–12 (mg•hr/L) 39.66 ± 8.70 37.56 ± 9.95 32.84 ± 8.43
MPA C0 (mg/L) 1.80 ± 0.78 1.54 ± 1.28 1.48 ± 0.54
Cmax (mg/L) 14.10 ± 5.18 10.88 ± 4.00 9.40 ± 3.16
Tmax (hrs) 1.04 ± 0.98 1.99 ± 2.24 1.00 ± 0.00
MMF = mycophenolate mofetil; AUC0–12 = area under the concentration-time curve from 0–12 hours; MPA=
mycophenolic acid; C0 = predose plasma concentration; Cmax = maximum concentration; Tmax = time to reach Cmax.
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administered with ferrous sulfate (210 mg
elemental iron) in healthy volunteers.20 The
investigators theorized that the decrease was
secondary to the development of an insoluble
iron-MMF complex.  However, results of a later
in vitro investigation did not support this
theory.22 Our study was designed to investigate
the effect of two iron formulations—slow-release
ferrous sulfate and polysaccharide iron
complex—on the pharmacokinetics of MPA to
determine true steady-state concentrations of
each drug in renal transplant recipients.
Slow-Release Ferrous Sulfate
Overall systemic exposure to MPA was not
altered with concomitant slow-release ferrous
sulfate and MMF in stable renal transplant
recipients.  In addition, 2-hour dosing separation
had no effect on the relative bioavailability of
MMF. These results are strikingly dissimilar from
those previously reported.20 These differences
were possibly due to the previous trial ’s
evaluation of a healthy population, use of twice
the dose of elemental iron, or, most likely, use of
a single-dose design.20 Our study reflected
steady-state MPA exposure in renal transplant
patients (at least 6 mo after transplantation) who
received concomitant or dose-separated ferrous
sulfate with MMF 1000 mg twice/day.
While our study was ongoing, other researchers
tested hypotheses in renal transplant recipients
similar to ours.23, 24 One group measured
AUC0–12 values for MPA on day 5 after de novo
renal transplantation.24 Another group created a
single-dose design and measured AUC0–12 values
for MPA in renal transplant recipients at least 6
months after transplantation.23 Both evaluated a
formulation of ferrous sulfate iron.  Our trial was
effectively a hybrid of these two studies.
Although we enrolled somewhat fewer patients
than the others did, our conclusions regarding
ferrous sulfate were similar to theirs.
Investigators recently repeated the nonfed-state
study design previous researchers used20 by
administering MMF 1 g alone or with oral slow-
release ferrous sulfate to healthy volunteers.25
Their aim was to confirm the reported interaction
between ferrous sulfate and MMF.  However, the
results were dissimilar to the previous findings.
Like us, they found no notable alteration in the
pharmacokinetic profile of MMF when it was
coadministered with iron.  Given the similar
designs of the two trials, the authors suggested
that the difference might have been attributable
to confounders associated with bioanalytic assays
used in the original study.20, 25
Our trial and the above-mentioned trials add to
the body of robust evidence demonstrating the
lack of interaction when ferrous sulfate is
coadministered with MMF.
Polysaccharide Iron Complex
The results surprisingly demonstrated a
significant increase in overall systemic exposure
of MPA during the dose-separation phase with
polysaccharide iron complex.  In addition, mean
AUCs for MPA increased in the concomitant-
administration phase, although the changes were
not statistically significant.  The magnitude of the
difference was similar for the mean and median
values of those groups as well.  A peculiar
observation was that the interaction was enhanced
during the dose-separation phase.  This finding
was inconsistent with those of our investigation
of a ferrous sulfate product and with the results
of three published reports.20, 23, 24 The increased
exposure may be attributed to chemical
differences in the polysaccharide iron complex
compared with the ferrous sulfate salt, to
alterations in the gastric environment that
benefited MMF absorption of this product, to
interpatient variability, or, most likely, to the
small sample size.
Most important, our data suggested that overall
exposure to MPA was not decreased after the
concomitant or delayed administration of ferrous
sulfate and polysaccharide iron complex.
Further in vitro studies may be required to
elucidate the pathway responsible for the
influence of polysaccharide iron complex on the
absorption of MPA.
Study Limitations
Limitations of this trial include the relatively
small sample size, the primarily Caucasian
population, the unavailability of the area under
the concentration-time curve for cyclosporine
when the pharmacokinetics of MPA were being
studied, and the nonfed-state study design.  The
limited sample affected the statistical power for
the two pharmacokinetic studies.  These flaws
may limit overall generalizability of the results to
the renal transplant population.
Because we did not study cyclosporine
pharmacokinetics, we cannot rule out effects of
cyclosporine on concentrations of MPA.
However, of note, the same dosage regimens for
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calcineurin inhibitors, MMF, prednisone, and any
other drugs were maintained in all patients
throughout the study.
Finally, during this study, three other groups of
investigators reported the lack of potential effect
of ferrous sulfate on the pharmacokinetics of
MPA.23–25 However, previous investigations
focused on the effect of a single dose of ferrous
sulfate or reflected the pharmacokinetics of MPA
5 days after transplantation.  By contrast, our
trial reflected true steady-state pharmacokinetics
for MPA and iron.  In addition, we investigated
the influence of two commonly prescribed
products in the United States.
Conclusion
In stable renal transplant recipients, oral
absorption of MMF was not reduced with
polysaccharide iron complex or slow-release
ferrous sulfate administered with or 2 hours after
MMF ingestion.
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